Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Sheridan, C. First Axl inhibitor enters clinical trials. Nat Biotechnol 31, 775–776 (2013). https://doi.org/10.1038/nbt0913-775a
Published:
Issue Date:
DOI: https://doi.org/10.1038/nbt0913-775a
- Springer Nature America, Inc.
This article is cited by
-
The great escape: tumour cell plasticity in resistance to targeted therapy
Nature Reviews Drug Discovery (2020)
-
Targeting Gas6/TAM in cancer cells and tumor microenvironment
Molecular Cancer (2018)
-
Dual gene activation and knockout screen reveals directional dependencies in genetic networks
Nature Biotechnology (2018)
-
Epithelial-to-mesenchymal transition in cancer: complexity and opportunities
Frontiers of Medicine (2018)
-
EMT, CSCs, and drug resistance: the mechanistic link and clinical implications
Nature Reviews Clinical Oncology (2017)